Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review0856 has been discontinued.
View all Non-selective Metabotropic Glutamate products.Group I/group II mGlu antagonist at cloned receptors.
M. Wt | 223.23 |
Storage | Store at RT |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Bedingfield et al (1995) Structure-activity relationships for a series of phenylglycine derivatives at metabotropic glutamate receptors (mGluRs). Br.J.Pharmacol. 116 3323 PMID: 8719814
Sekiyama et al (1996) Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. Br.J.Pharmacol. 117 1493 PMID: 8730745
Watkins and Collingridge (1994) Phenylglycine derivatives as antagonists of metabotropic glutamate receptors. TiPS 15 333 PMID: 7992387
Keywords: (RS)-a-Methyl-3-carboxymethylphenylglycine, (RS)-a-Methyl-3-carboxymethylphenylglycine supplier, Non-selective, mGlu, 0856, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for (RS)-α-Methyl-3-carboxymethylphenylglycine.
There are currently no reviews for this product. Be the first to review (RS)-α-Methyl-3-carboxymethylphenylglycine and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.